KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) issued its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.04), MarketWatch Earnings reports. KalVista Pharmaceuticals Stock Performance Shares of NASDAQ KALV opened at $8.16 on Friday. The company has a 50 […]
KalVista Pharmaceuticals (NASDAQ:KALV) Releases Earnings Results, Misses Expectations By $0 04 EPS kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
- Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Targeted Number of Attacks to Complete Trial -
- Data Readout on Track for Early 2024; NDA Filing Expected H1 2024 -
.
England - KalVista Pharmaceuticals, Inc. , today announced that the compensation committee of KalVista s board of directors granted four newly-hired employees inducement options to purchase an.